In this week’s Parallax, host Ankur Kalra is joined by Charles (Chuck) Simonton, Vice President and Chief Medical Officer of Abiomed. Chuck talks about how his father’s leadership and service as a Methodist minister inspired him to become a doctor. He recalls the dawn of interventional cardiology: the birth of angioplasty and stenting. Drawing from his experiences as a trialist who worked with some of the most influential minds, he offers practical tips to young doctors. Finally, Ankur asks Chuck about the Impella device controversy and the recent decision of Abiomed to accelerate their clinical research.
How should you start building a research programme? What are Chuck Simonton’s thoughts on the relationship between doctors and the industry? What is Chuck’s message to young cardiologists?
Tune in to listen to this week’s episode of Parallax.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.
Submit your questions to Ankur via: podcast@radcliffe-group.com.
During her interventional cardiology fellowship, Dr Baron became fascinated by the implementation of novel technologies. She earned her degree in Clinical Epidemiology and spent a year working at the FDA’s Device Evaluation unit.
In 2019 Dr Baron presented the results of her late-breaking trial, COAPT. Ankur invites Suzanne to discuss the economic analysis of the study and to give a short introduction to cost-effectiveness analysis. Suzanne provides an overview of the trial and they talk about the importance of understanding the value and benefits of new devices from both the patient and the health-economic point of viewpoint.
Ankur is back with his second #AudioArticle! This week he spoke with Santiago Garcia from the Minneapolis Heart Institute about Santiago’s US Cardiology Review 13.1 article on the role of high-sensitivity cardiac troponin (hscTn) assays and their ability to rapidly rule in or rule out acute coronary syndrome (ACS) with improved sensitivity.
Chest pain is one of the most common reasons for an emergency room visit in the US, with almost 6 million ER visits annually, yet there is no consensus on how to compare the results from various hscTn assays. Tune in to hear Santiago outline the advantages and limitations of using hscTn as a standard biomarket to evaluate patients with suspected ACS in the ER.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.
Having recently applied for the programme himself, Ankur also speaks with Hari about the history, purpose and future of the Society for Cardiovascular Angiography and Interventions (SCAI) Emerging Leader Mentorship (ELM) Fellowship Programme. Submit your question to: podcast@radciffe-group.com. Guest @SrihariNaiduMD.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.
In the final episode of our burnout and resilience series, Kavitha and Ankur give you some practical tools of self-care to help you avoid burnout. Kavitah Chinnaiyan, MD, is an award-winning author and, Cardiologist and Director of Cardiac CT Research at Beaumont Health, MI. Send us your thoughts to this episode for Ankur to share in future episodes: podcast@radciffe-group.com. Guest @ChinnaiyanMD.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.
In our second episode on burnout and resilience, Kavitah Chinnaiyan, MD, and Ankur take a deeper dive into mindfulness and training the brain to move from Default-Mode to Task-Positive Networks. Kavitah is an award-winning author and, Cardiologist and Director of Cardiac CT Research at Beaumont Health, MI. Send us your thoughts to this episode for Ankur to share in future episodes: podcast@radciffe-group.com. Guest @ChinnaiyanMD.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.
Ankur and Madhav also discuss positive traits of leadership, why we should embrace failure and the importance of mentorship throughout all stages of one’s medical career. Send us your comments to this episode for Ankur to share in future episodes: pocast@radciffe-group.com. Guest @mswami001.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.